The impact of GLP-1 RAs on mortality, MACEs, and MAKEs The crude incidence of mortality rate was 22.91 per 1000 person-years, which was significantly lower in the GLP-1 RAs users group than in the non-users group (6.8% vs
According to a Kaiser Family Foundation report, only ~13 Medicaid programs covered GLP-1 weight-loss indications as of late 2024 ( [24] ), and major insurers have at times dropped GLP-1 coverage for obesity after high spending ( [25] )
Additionally, many Crohn's disease patients experience metabolic complications, including insulin resistance and weight changes related to corticosteroid use
This class of prescription medications can help lower insulin secretion and delay gastric emptying
J Assist Reprod Genet 32:635643 Zhanga J, Arshadb Kh, Siddiqueb R, Xuc H, Alshammarid A, Albekairid NA, Rashid Bazmie R, Hussainb IHL (2024) Rubia cordifolia in letrozole-induced PCOS
Wang F, Lu Y, Qi F, Su Q, Wang L, You C, et al